69 results
8-K
EX-3.2
EQRX
EQRx, Inc.
9 Nov 23
Completion of Acquisition or Disposition of Assets
9:29am
Member, each of whom shall serve as an officer until his or her death, resignation, removal or disqualification or until his or her replacement … , of the Company under any contract to which the officer is a party.
(e) A vacancy in any office of the Company because of death, resignation, removal
DEFM14A
EQRX
EQRx, Inc.
29 Sep 23
Proxy related to merger
4:38pm
-programmed death-ligand 1 (PD-L1) antibody, which was in-licensed from CStone Pharmaceuticals in 2020. The other clinical-stage programs in EQRx’s pipeline … for the treatment of patients with metastatic breast cancer; (ii) nofazinlimab, an anti-programmed death-1 (PD-1) antibody being evaluated for the treatment
425
EQRX
EQRx, Inc.
1 Aug 23
Business combination disclosure
5:22pm
Surviving Corporation until their successors have been duly elected or appointed and qualified or until their earlier death, resignation or removal … , be the managing member of the Surviving Company until its successor has been duly elected or appointed and qualified or until its earlier death, resignation
425
EQRX
EQRx, Inc.
1 Aug 23
Business combination disclosure
7:25am
Surviving Corporation until their successors have been duly elected or appointed and qualified or until their earlier death, resignation or removal … , be the managing member of the Surviving Company until its successor has been duly elected or appointed and qualified or until its earlier death, resignation
8-K
EX-2.1
sd9q9pz59
1 Aug 23
Form of Parent Stockholder Voting Agreement
7:19am
8-K
EX-99.2
y5r0sb4
1 Aug 23
Form of Parent Stockholder Voting Agreement
7:19am
425
mmrujj9
1 Aug 23
Business combination disclosure
7:15am
8-K
EX-99.1
lgidvss2tita jcn2
8 May 23
Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results
4:08pm
424B3
4a6imcheo6twq9xri
10 Nov 22
Prospectus supplement
7:24pm
8-K
w3ngt24a4s7wpuypm33
3 Oct 22
Submission of Matters to a Vote of Security Holders
4:54pm
DEF 14A
47fx32bw2jpd222yiy
12 Aug 22
Definitive proxy
4:05pm
424B3
0op9eptbb3r
11 Aug 22
Prospectus supplement
9:21pm
8-K
EX-99.1
pkl7gtrndlo
11 Aug 22
EQRx Reports Second Quarter 2022 Financial Results and Recent Corporate Progress
7:07am
424B3
xqqa0 nmf7uy8u9
13 May 22
Prospectus supplement
5:24pm
POS AM
zywvlt62m5xppx6p 1df
23 Mar 22
Prospectus update (post-effective amendment)
6:30pm
10-K
o3wrmdi99v5pt
23 Mar 22
Annual report
4:43pm